Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.

Arthritis and rheumatism - 1 Jun 2007

Wessels Judith A M, van der Kooij Sjoerd M, le Cessie Saskia, Kievit Wietske, Barerra Pilar, Allaart Cornelia F, Huizinga Tom W J, Guchelaar Henk-Jan

Abstract excerpt

OBJECTIVE: To develop a clinical pharmacogenetic model to predict the efficacy of methotrexate (MTX) in rheumatoid arthritis (RA). METHODS: Two hundred five patients with newly diagnosed RA and active disease were treated with MTX (initiated at a dosage of 7.5 mg/week and increased to 15 mg/week...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to AMP Deaminase
Share to Antirheumatic Agents
Share to Arthritis, Rheumatoid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxymethyl and Formyl Transferases

Share to Methotrexate

Share to Multienzyme Complexes

Share to Pyrophosphatases

Share to Rheumatoid Factor

Source

Identifiers

PMID: 17530705
DOI: 10.1002/art.22640

Genes

AMPD1
ATIC
ITPA
MTHFD1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17530705-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis.PMID 17530705Read ↗

Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis.Semantic proximity Read ↗

Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis.Semantic proximity Read ↗

Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients.Semantic proximity Read ↗

Methotrexate Pharmacogenetics in the Treatment of Rheumatoid ArthritisSemantic proximity Read ↗

Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis.Semantic proximity Read ↗

Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms.Semantic proximity Read ↗

Methotrexate: Implications of pharmacogenetics in the treatment of patients with Rheumatoid Arthritis.Semantic proximity Read ↗

Methotrexate pharmacogenetics in rheumatoid arthritis: a status report.Semantic proximity Read ↗

The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients.Semantic proximity Read ↗

Prediction of clinical non-response to methotrexate treatment in juvenile idiopathic arthritis.Semantic proximity Read ↗

Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?Semantic proximity Read ↗

Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.